Literature DB >> 25932596

Efficacy of treatments for anxiety disorders: a meta-analysis.

Borwin Bandelow1, Markus Reitt, Christian Röver, Sophie Michaelis, Yvonne Görlich, Dirk Wedekind.   

Abstract

To our knowledge, no previous meta-analysis has attempted to compare the efficacy of pharmacological, psychological and combined treatments for the three main anxiety disorders (panic disorder, generalized anxiety disorder and social phobia). Pre-post and treated versus control effect sizes (ES) were calculated for all evaluable randomized-controlled studies (n = 234), involving 37,333 patients. Medications were associated with a significantly higher average pre-post ES [Cohen's d = 2.02 (1.90-2.15); 28,051 patients] than psychotherapies [1.22 (1.14-1.30); 6992 patients; P < 0.0001]. ES were 2.25 for serotonin-noradrenaline reuptake inhibitors (n = 23 study arms), 2.15 for benzodiazepines (n = 42), 2.09 for selective serotonin reuptake inhibitors (n = 62) and 1.83 for tricyclic antidepressants (n = 15). ES for psychotherapies were mindfulness therapies, 1.56 (n = 4); relaxation, 1.36 (n = 17); individual cognitive behavioural/exposure therapy (CBT), 1.30 (n = 93); group CBT, 1.22 (n = 18); psychodynamic therapy 1.17 (n = 5); therapies without face-to-face contact (e.g. Internet therapies), 1.11 (n = 34); eye movement desensitization reprocessing, 1.03 (n = 3); and interpersonal therapy 0.78 (n = 4). The ES was 2.12 (n = 16) for CBT/drug combinations. Exercise had an ES of 1.23 (n = 3). For control groups, ES were 1.29 for placebo pills (n = 111), 0.83 for psychological placebos (n = 16) and 0.20 for waitlists (n = 50). In direct comparisons with control groups, all investigated drugs, except for citalopram, opipramol and moclobemide, were significantly more effective than placebo. Individual CBT was more effective than waiting list, psychological placebo and pill placebo. When looking at the average pre-post ES, medications were more effective than psychotherapies. Pre-post ES for psychotherapies did not differ from pill placebos; this finding cannot be explained by heterogeneity, publication bias or allegiance effects. However, the decision on whether to choose psychotherapy, medications or a combination of the two should be left to the patient as drugs may have side effects, interactions and contraindications.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25932596     DOI: 10.1097/YIC.0000000000000078

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  79 in total

Review 1.  The Use of Virtual Reality Technology in the Treatment of Anxiety and Other Psychiatric Disorders.

Authors:  Jessica L Maples-Keller; Brian E Bunnell; Sae-Jin Kim; Barbara O Rothbaum
Journal:  Harv Rev Psychiatry       Date:  2017 May/Jun       Impact factor: 3.732

2.  Constitutive plasma membrane monoamine transporter (PMAT, Slc29a4) deficiency subtly affects anxiety-like and coping behaviours.

Authors:  T Lee Gilman; Christina M George; Melissa Vitela; Myrna Herrera-Rosales; Mohamed S Basiouny; Wouter Koek; Lynette C Daws
Journal:  Eur J Neurosci       Date:  2018-05-24       Impact factor: 3.386

3.  The efficacy of benzodiazepines as acute anxiolytics in children: A meta-analysis.

Authors:  Heide Kuang; Jessica A Johnson; Jilian M Mulqueen; Michael H Bloch
Journal:  Depress Anxiety       Date:  2017-05-15       Impact factor: 6.505

Review 4.  [Guideline-oriented inpatient psychiatric psychotherapeutic/psychosomatic treatment of anxiety disorders : How many personnel are need?].

Authors:  B Bandelow; U Lueken; J Wolff; F Godemann; C Wolff-Menzler; J Deckert; A Ströhle; M Beutel; J Wiltink; K Domschke; M Berger
Journal:  Nervenarzt       Date:  2016-03       Impact factor: 1.214

Review 5.  Herbal medicine for depression and anxiety: A systematic review with assessment of potential psycho-oncologic relevance.

Authors:  K Simon Yeung; Marisol Hernandez; Jun J Mao; Ingrid Haviland; Jyothirmai Gubili
Journal:  Phytother Res       Date:  2018-02-21       Impact factor: 5.878

6.  Biofeedback to treat anxiety in young people at clinical high risk for developing psychosis.

Authors:  Laina McAusland; Jean Addington
Journal:  Early Interv Psychiatry       Date:  2016-08-29       Impact factor: 2.732

7.  The Diagnosis and Treatment of Anxiety Disorders.

Authors:  Andreas Ströhle; Jochen Gensichen; Katharina Domschke
Journal:  Dtsch Arztebl Int       Date:  2018-09-14       Impact factor: 5.594

Review 8.  The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive Disorders.

Authors:  Baptiste Pignon; Chloé Tezenas du Montcel; Louise Carton; Antoine Pelissolo
Journal:  Curr Psychiatry Rep       Date:  2017-11-07       Impact factor: 5.285

Review 9.  Comorbid autism spectrum disorder and anxiety disorders: a brief review.

Authors:  Brian A Zaboski; Eric A Storch
Journal:  Future Neurol       Date:  2018-01-17

Review 10.  The Good, the Bad and the Unknown Aspects of Ghrelin in Stress Coping and Stress-Related Psychiatric Disorders.

Authors:  Eva Maria Fritz; Nicolas Singewald; Dimitri De Bundel
Journal:  Front Synaptic Neurosci       Date:  2020-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.